Related Experiment Video
Updated: Jun 3, 2026
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Published on: November 19, 2019
KRAS-driven immune exclusion in pancreatic ductal adenocarcinoma: mechanisms and therapeutic reversal
1Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego, CA, USA.
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) remains largely resistant to immunotherapy, with response rates below 5%. Emerging evidence suggests that immune exclusion in PDAC is actively maintained by oncogenic KRAS signaling. Mechanistic studies implicate three coordinated processes: autophagy-mediated degradation of MHC-I and impaired antigen presentation, expansion of suppressive myeloid populations, and desmoplastic stromal remodeling that restricts cytotoxic T-cell access to malignant epithelium. These barriers are at least partially reversible. Inhibition of autophagy restores surface MHC-I expression and re-enables antigen-dependent CD8+ T-cell killing. Suppression of KRAS pathway signaling remodels the myeloid compartment, alters stromal architecture, and increases intratumoral CD8+ T-cell infiltration in experimental systems. Recent studies further demonstrate that combining allele-specific KRAS inhibition with multi-arm immunotherapy can produce durable responses in resistant PDAC models. Spatial profiling data also suggest that immune architecture differs by KRAS allele, with KRAS G12D tumors more frequently exhibiting stromal T-cell segregation and KRAS G12R tumors demonstrating altered immune proximity and metabolic dependence. Together, these findings support a model in which KRAS-targeted therapy functions not only as tumoricidal therapy but also as immune conditioning of the tumor microenvironment. Translating this biologic reversibility into durable clinical benefit will require rational, barrier-specific, and allele-informed combination strategies.
Insights
Pancreatic cancer (PDAC) is resistant to immunotherapy due to KRAS signaling. Targeting KRAS and related pathways can overcome immune exclusion and improve treatment response.
Area of Science:
- Oncology
- Immunology
- Cancer Biology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) exhibits profound resistance to immunotherapy, with response rates below 5%.
- Oncogenic KRAS signaling is implicated in actively maintaining immune exclusion within the PDAC tumor microenvironment.
- Key barriers include autophagy-mediated MHC-I degradation, suppressive myeloid cell expansion, and stromal remodeling hindering T-cell infiltration.
Purpose of the Study:
- To investigate the mechanisms of immune exclusion in PDAC driven by KRAS signaling.
- To explore the reversibility of these immune-suppressive barriers through targeted therapies.
- To evaluate the potential of combining KRAS-targeted therapies with immunotherapy for resistant PDAC.
Main Methods:
- Mechanistic studies analyzing autophagy, antigen presentation, myeloid populations, and stromal remodeling.
- Experimental models assessing the effects of autophagy inhibition and KRAS pathway suppression.
- Spatial profiling to analyze immune architecture differences based on KRAS allele status (G12D vs. G12R).
Main Results:
- Inhibition of autophagy restores MHC-I expression and CD8+ T-cell mediated killing.
- KRAS pathway suppression remodels the myeloid compartment, alters stroma, and increases intratumoral CD8+ T-cell infiltration.
- Combining allele-specific KRAS inhibition with immunotherapy yields durable responses in PDAC models; immune architecture varies by KRAS allele.
Conclusions:
- KRAS-targeted therapy can reverse immune exclusion in PDAC, acting as both tumoricidal and immune-conditioning treatment.
- Reversibility of immune barriers is achievable, suggesting potential for durable clinical benefit.
- Rational, barrier-specific, and allele-informed combination strategies are crucial for translating these findings into clinical practice.
Related Concept Videos
01:25Chronic Pancreatitis I: Introduction
01:21Chronic Pancreatitis II: Pathophysiology